Composition and method for compounded therapy
The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously; may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients; and may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, other active ingredients, and DMSO or Sterile Water for Irrigation. In another aspect, the present embodiments relate to methods of compounding medications and transdermal creams or gels.
1. A method of making a compounded transdermal cream, the method comprising:
grinding up one or more tablets of a Non-Steroidal Anti-Inflammatory Drug (NSAID) to produce a fine powder, wherein the NSAID comprises meloxicam;
grinding up one or more tablets of an anticonvulsant to produce a fine powder, wherein the anticonvulsant comprises lamotrigine;
wetting the ground fine powders with dimethyl sulfoxide (DMSO) or Sterile Water for Irrigation; and
adding the wetted ground fine powders to a eutectic mixture of lidocaine and prilocaine in an emulsified topical cream in the form of a lidocaine 2.5%-prilocaine 2.5% cream to form a compounded transdermal cream, wherein the compounded transdermal cream comprises between 0.05% and 0.15% by weight meloxicam, between 2.0% and 3.0% by weight lamotrigine, and at least 80% by weight of the eutectic mixture comprising lidocaine and prilocaine in an emulsified topical cream in the form of a lidocaine 2.5%-prilocaine 2.5% cream, wherein the compounded transdermal cream comprises at least 2.0% by weight lidocaine and at least 2.0% by weight prilocaine.
2. The method of claim 1 , wherein the compounded transdermal cream comprises approximately 0.09% by weight meloxicam.
3. The method of claim 1 , wherein the compounded transdermal cream comprises approximately 2.5% by weight lamotrigine and/or topiramate.
4. The method of claim 1 , wherein the compounded transdermal cream comprises 0.0 9% by weight meloxicam and 2.5% by weight lamotrigine.
5. The method of claim 1 , further comprising grinding up one or more tablets of a nerve depressant, a muscle relaxant, a N-Methyl-D-aspartate (NMDA) receptor antagonist, an opiate or opioid agonist, or an antidepressant to produce a fine powder, wherein the compounded transdermal cream comprises 0.1% by weight of meloxicam and 5.0% by weight of the nerve depressant, muscle relaxant, NMDA receptor antagonist, opiate or opioid agonist, or antidepressant.